South University, SavannahNSG 6320AGNP BOARD EXAM QUESTIONS Neurology Prescribing .WITH ANSWERS 2021

Document Content and Description Below

AGNP BOARD EXAM QUESTIONS Neurology Assessment (102 Questions) Question: Which of the following medications is NOT a serotonin 5-HT1 receptor agonist? Axert. Fioricet. Correct Maxalt. Zomig. Ex... planation: Fioricet is a combination of butalbital, acetaminophen and caffeine. Axert (almotriptan), Maxalt (rizatriptan), Zomig (zolmitriptan) are all classified as serotonin 5-HT1 receptor agonists, or triptans. Question: A patient presenting with a transient ischemic attack (TIA) is taking nifedipine (Adalat CC) for hypertension. Pharmacokinetics of nifedipine may be altered in patients with: renal insufficiency. hepatic impairment. Correct irritable bowel disease. G6PD deficiency. Explanation: Since hepatic biotransformation is the predominant route for the disposition of nifedipine, the pharmacokinetics may be altered in patients with chronic liver disease. Patients with hepatic impairment have a longer disposition half-life and higher bioavailability of nifedipine than healthy volunteers. Question: Oxcarbazepine (Trileptal) is structurally similar to: carbamazepine (Tegretol). Correct divalproex sodium (Depakote). lamotrigine (Lamictal). topiramate (Topamax). Explanation: As the name suggests, oxcarbazepine (Trileptal) is related to carbamazepine (Tegretol, Carbatrol) and appears to be similarly effective for controlling complex partial seizures and primary and secondary generalized tonic-clonic seizures. It seems to cause fewer unwanted side effects in many (but not all) patients. Oxcarbazepine is not effective against absence or myoclonic seizures. Question: Patients who experience greater than 7 to 9 tension-type headaches per month may be considered for maintenance therapy including: anticonvulsants and tricyclic antidepressants. antidepressants and beta-blockers. anticonvulsants and muscle relaxants. muscle relaxants and tricyclic antidepressants. Correct Explanation: Patients who experience greater than 7 to 9 tension-type headaches per month may be considered for maintenance therapy including muscle relaxants (i.e., tizanidine) and tricyclic antidepressants (i.e., amitriptyline). Muscle relaxants are considered secondline therapy to be added to TCAs if inadequate in reducing headache episodes. Antiepileptics and beta-blockers may be indicated for the prophylactic treatment of migraines. There is more evidence of effectiveness with amitriptyline than doxepin, or with other antidepressants such as venlafaxine and mirtazapine. Doses used are generally low and not in the range used to treat depression. The need for continued chronic treatment of tension-type headaches should be reviewed at least every 6 months. [Show More]

Last updated: 1 year ago

Preview 1 out of 33 pages